On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


ChineseInvestors.com, Inc. (CIIX) Focuses on Providing Financial Information and Services

  • ChineseInvestors.com is a fintech company
  • It provides financial information for Chinese-speaking investors
  • The company is in the process of spinning off its cannabidiol (CBD) division

ChineseInvestors.com, Inc. (OTCQB: CIIX) is a fintech company that concentrates on providing financial information and services. Its focus is on operating the foremost financial information website for Chinese-speaking investors. The company provides real-time market commentary, analysis and education-related services via www.ChineseFN.com. ChineseInvestors.com has corporate offices in San Gabriel, California; New York, New York; and Shanghai, China.

Furthermore, the company has recognized opportunities in the U.S. cannabis industry. It has worked to take advantage of the increasing demand for cannabidiol-based nutrition and health products. However, its intention is to focus back on its original mission of providing financial information and services to the greater Chinese community in the United States and internationally. As a result, ChineseInvestors.com is progressing on its initiative to spin off its CBD division, ChineseHempOil.com, Inc.

On January 31, 2017, the company formally launched the website for subsidiary ChineseCBDoil.com. This portal is the world’s first CBD health products online store in the Chinese language. The website offers an array of nutritional supplements containing CBD. Products include purified CBD oil; concentrated CBD; CBD extract liquid; CBD balm; CBD food; and CBD drinks. These offerings are targeted at Chinese-speaking customers around the world.

Warren Wang, ChineseInvestors.com’s chief executive officer, is hopeful that the spinoff of the company’s CBD subsidiary, ChineseHempOil.com, Inc., will be completed by the end of 2018. In a news release, Wang stated, “We intend to continue to expand our consumer division by dedicating more resources to marketing hemp-based CBD products both domestically and in China. At the same time, we will continue to offer our core financial subscription services with a focus on increasing subscription revenues through targeted marketing of the company’s new cryptocurrency subscription services and educational products.”

The drive to legalize hemp is gaining traction. Forbes reported recently that the U.S. Senate voted to legalize hemp after a decades-long ban under marijuana prohibition (http://ibn.fm/B1LUZ). Therefore, to meet the growing demand, ChineseHempOil.com is planning to expand its operations to more U.S. States, as well as Canada and Asian markets (http://ibn.fm/fZ0iH).

ChineseInvestors.com’s CBD division is an attractive asset. For fiscal year 2018, the company reported a 41 percent year-over-year increase in revenues. It ascribes most of the growth to consumer product sales via its wholly owned subsidiaries, ChineseHempOil.com Inc. and CBD Biotechnology Co., Ltd.

Nonetheless, the company, upon completion of its CBD assets spin off, will return to its foundation in consulting, brand building and education for the Chinese-speaking community. While strategically centering on CBD hemp sales, it also has plans to create a cryptocurrency ATM network and a domestic online coin-to-coin exchange for Chinese cryptocurrency investors (http://ibn.fm/X94xT). ChineseInvestors.com continually seeks new growth channels to build its business and shareholder value.

For more information, visit the company’s website at www.ChineseInvestors.com

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.